Brief: Cstone And Pfizer Announce NMPA Approval Of Sugemalimab In Patients With Unresectable Stage III Non-Small Cell Lung Cancer
06/06/2022 05:26
June 6 (Reuters) - CStone Pharmaceuticals 2616.HK :
* CSTONE AND PFIZER ANNOUNCE NMPA APPROVAL OF SUGEMALIMAB IN
PATIENTS WITH UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER
Source text for Eikon: ID:nPn7P0kySa
Further company coverage: 2616.HK
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on CStone Pharmaceuticals
See all newsBrief: CStone Pharmaceuticals Says CEO Purchases 496,000 Shares For Over HK$2.7 Million From Sept 17-22
Brief: CStone Pharmaceuticals Posts HY Loss Of Rmb252.3 Million
China's CStone Pharmaceuticals H1 revenue soars on drug sales
Brief: Cstone Pharmaceuticals Receives NMPA IND Approval For CS5007 In China
Brief: CStone Pharmaceuticals Says Directors And Senior Management Purchase 2.4 Million Shares In June 2026